Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

CHS-131, A Novel Once Daily Oral Treatment, Decreased Lesion Burden of Patients with Relapsing-Remitting Course of Multiple Sclerosis (RRMS) in a Randomized, Double-blind, Phase 2b, Multicenter Study
Multiple Sclerosis
S50 - (-)
002
Authors/Disclosures
David Weinstein, MD, PhD (Apellis Pharmaceuticals)
PRESENTER
No disclosure on file
Alexey Boyko, MD, PhD (FCCPSMS Center At Usupov's Hospital) No disclosure on file
Lisa Pugliese No disclosure on file
No disclosure on file
No disclosure on file
Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center) The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Filterlex. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for 3D Communications. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurology Live. The institution of Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
Barbara Finck, MD No disclosure on file